Related Experiment Video
Updated: Jul 6, 2026
07:37
An Adoptive Transfer Model of Rheumatoid Arthritis in Mice
Published on: June 6, 2025
Pharmacogenomics in rheumatoid arthritis
1Department of Medicine, Washington University School of Medicine, St. Louis, Missouri, USA.
Methods in Molecular Biology (Clifton, N.J.)
|March 29, 2008
Summary
Pharmacogenomics can personalize rheumatoid arthritis (RA) treatment by predicting patient response to disease-modifying antirheumatic drugs (DMARDs). This approach aims to improve efficacy and reduce toxicity for RA patients.
Area of Science:
- Rheumatology
- Pharmacogenomics
- Immunology
Background:
- Rheumatoid arthritis (RA) is a systemic inflammatory condition causing severe joint damage, high morbidity, and mortality.
- Disease-modifying antirheumatic drugs (DMARDs) are standard RA treatments, alleviating symptoms and inhibiting radiographic progression.
- Biologic agents represent a newer class of DMARDs, but patient responses vary significantly in efficacy and toxicity.
Purpose of the Study:
- To review the current literature on the pharmacogenomics of traditional and biologic DMARDs in RA.
- To explore the potential of pharmacogenomics in predicting individual patient responses to RA therapies.
- To highlight how pharmacogenomics may enable individualized drug therapy for RA patients.
Main Methods:
- Literature review of published studies on pharmacogenomics of DMARDs in rheumatoid arthritis.
- Analysis of existing data on patient response variability to traditional and biologic DMARDs.
- Synthesis of findings to assess the predictive value of pharmacogenomics for RA treatment.
Main Results:
- Patient responses to DMARDs, including biologic agents, show considerable variability in both efficacy and toxicity.
- Currently, reliable methods for predicting individual patient response to specific DMARDs before treatment initiation are lacking.
- Pharmacogenomic studies offer insights into genetic factors influencing DMARD response in RA.
Conclusions:
- Pharmacogenomics holds promise for personalizing rheumatoid arthritis treatment strategies.
- Individualized drug therapy based on genetic profiles could optimize DMARD selection for RA patients.
- Future research in RA pharmacogenomics may lead to improved treatment outcomes and reduced adverse effects.
Related Concept Videos
01:29Pharmacogenomics: Identification of New Drug Targets
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
01:29Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
01:11Genome-wide Association Studies-GWAS
Genome-wide association studies or GWAS are used to identify whether common SNPs are associated with certain diseases. Suppose specific SNPs are more frequently observed in individuals with a particular disease than those without the disease. In that case, those SNPs are said to be associated with the disease. Chi-square analysis is performed to check the probability of the allele likely to be associated with the disease.
GWAS does not require the identification of the target gene involved in...
GWAS does not require the identification of the target gene involved in...
01:29Pharmacogenetics and Pharmacogenomics: Overview
Pharmacogenetics and pharmacogenomics examine how genetic factors influence an individual's response to drugs. While pharmacogenetics focuses on the impact of specific genetic variants on drug effects, pharmacogenomics takes a broader approach, studying how genetic variation across populations contributes to differences in drug responses. These fields aim to explain why individuals may experience varying levels of efficacy or adverse reactions to the same medication.Variability in drug...
01:27Pharmacogenetics of Drug Metabolism: Overview
Genetic polymorphism in drug metabolism is crucial to the inter-individual variability observed in drug responses. Drug metabolism primarily involves the chemical modification of drugs and other xenobiotics to enhance their elimination by increasing their polarity. Two main classes of enzymes mediate this biotransformation process: Phase I enzymes, primarily cytochrome P450s, catalyze oxidation and reduction reactions, while other enzymes, such as esterases, mediate hydrolysis, and Phase II...
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...